A risk in the contract business for active pharmaceutical ingredients and intermediates and in the drug discovery business, where the success or failure of obtaining approvals, launching products and research and development affects sales and business plans. It also includes deterioration in the pharmaceutical segment's performance due to declining sales volumes of contracted products.